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Background: To evaluate whether the addition of bevacizumab (BVZ) to capecitabine-based chemoradiotherapy in
the preoperative treatment of locally advanced rectal cancer (LARC) improves efficacy measured by the pathological
complete response (pCR) rate.
Methods: A phase II two-step design was performed. Patients received four cycles of therapy consisting of: BVZ
10 mg/kg in first infusion on day 1 and 5 mg/kg on days 15, 29, 43, capecitabine 1800 mg/m2/day 5 days per week
during radiotherapy, which consisted of external-beam irradiation (45 Gy in 1.8 Gy dose per session over 5 sessions/
week for 5 weeks). Six to eight weeks after completion of all therapies surgery was undergone. To profile the biological
behaviour during BVZ treatment we measured molecular biomarkers before treatment, during BVZ monotherapy, and
during and after combination therapy. Microvessel density (MVD) was measured after surgery.
Results: Forty-three patients were assessed and 41 were included in the study. Three patients achieved a pathological
complete response (3/40: 7.5%) and 27 (67.5%) had a pathological partial response, (overall pathological response rate
of 75%). A further 8 patients (20%) had stable disease, giving a disease control rate of 95%. Downstaging occurred in 31
(31/40: 77.5%) of the patients evaluated. This treatment resulted in an actuarial 4-year disease-free and overall survival of
85.4 and 92.7% respectively. BVZ with chemoradiotherapy showed acceptable toxicity. No correlations were observed
between biomarker results and efficacy variables.
Conclusion: BVZ with capecitabine and radiotherapy seem safe and active and produce promising survival results in
LARC.
Trial registration: ClinicalTrials.gov Identifier NCT00847119. Trial registration date: February 18, 2009.
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Patients with locally advanced rectal cancer (LARC),
clinical stages II/III, are at risk of both locoregional and
distant failure. Advances in surgery, as total mesorectal
excision (TME) have improved local control [1-3].
nd neoadjuvant chemotherapy and radiation therapy
have significantly enhanced clinical outcome, in terms of
reduction in local recurrence and improvements in* Correspondence: mgarciamartin@iconcologia.net
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unless otherwise stated.sphincter-sparing surgeries [4]. Patients with a patho-
logical complete response (pCR) after preoperative
chemo-radiotherapy, have a clear advantage in terms of
disease-free survival (DFS) and overall survival (OS)
[5,6]. Attempts have been made in order to improve the
pCR of chemoradiation, further than using bolus or
continuous-infusion of 5-fluorouracil (5-FU) and radi-
ation. Capecitabine has the potential to significantly in-
crease the quality of life of patients during treatment,
but data comparing it with 5-FU are still early in devel-
opment and oxaliplatin has failed to show a benefit in
efficacy end points [7,8]. Among the most importantThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with this malignancy is the necessity to investigate new
treatments that can improve this rate of responders. In
addition, tumor regression after preoperative chemoradi-
ation has been suggested to be associated with smaller,
less aggressive disease and with the molecular tumor pro-
file regulating treatment response [5]. Bevacizumab (BVZ)
is an antibody against human vascular endothelial growth
factor (VEGF). Following the vascular normalization hy-
pothesis [9] although speculative, the advantage conferred
by the treatment with bevacizumab plus chemotherapy in
the treatment of colon cancer patients could be due to
increased tumour cell sensitivity to the action of the
chemotherapy or even the better delivery of chemotherapy
to tumours. Therefore it is of great interest to study com-
binations of BVZ and chemoradiation to improve the rate
of responders. The first study published with BVZ as pre-
operative treatment in LARC in combination with radio-
therapy by Willett et al. has been supplemented with final
results of the same study [10]. In this study, two of the
first 5 patients had dose-limiting toxicity, consisting of
diarrhoea and colitis during combination therapy. Con-
sequently, dose escalation was stopped and a dose of
5 mg/kg of BVZ was recommended for phase II. The
authors discussed the possibility that this toxicity (whose
profile seems to be as a result of radiotherapy) was due
to the elicitation of protective effect of VEGF on intes-
tinal damage caused by radiation therapy combined
with chemotherapy. The interesting thing was that pre-
cisely these patients were those who showed two patho-
logical complete responses after surgery. These authors
found a marked increase in apoptosis of tumour cells
on day +12, and a tendency to increased proliferation
was attributed to improved tumour microenvironment.
In line with the Willett group the aim of this study
was to explore the effects of a dose of BVZ in monother-
apy followed by concurrent treatment with BVZ, cape-
citabine and radiotherapy. The novelty of this study was
the administration of a mono-dose of BVZ 10 mg/kg,
followed by a lower dose in the concomitant setting in
which the effects of the single dose and the clinical,
pathological and biological effects after surgery were
studied.
The main objective of this study was to evaluate
whether the addition of BVZ to capecitabine-based che-
moradiotherapy in the preoperative treatment of LARC
improves efficacy measured by the pCR rate. Antiangio-
genic markers such as vascular endothelial growth factor
A (VEGF-A), vascular endothelial cadherin (VE-cadherin)
and microvessel density were evaluated in order to try to
correlate the results of expression of these markers with
the effect obtained on the tumor and also to assess the
prognostic value of these markers on the treatment out-
come in relation to other known prognostic markers [11].Methods
Patients
Eligible adult patients were required to have histologi-
cally confirmed locally advanced rectal adenocarcinoma
located < 15 cm from anal verge. The main inclusion
criteria were as follows: written informed consent prior
to any study related procedure, male and female aged 18
to 75 years, ECOG performance status 0 or 1, clinical
stage of T3, T4 with/without regional lymph node me-
tastases, no metastatic disease, no tumour haemorrhage
in the week prior to start of study treatment, external
derivation in symptomatic occlusive tumour, no prior
cancer treatment, adequate bone marrow, hepatic and
renal function and less than 10% weight loss. Patients
were excluded if they were not amenable to resection, or
presented any other malignancy which has been active
or treated within the past 5 years, with the exception of
in situ carcinoma of the cervix and non-melanoma skin
lesions adequately treated. No prior or concurrent
significant medical conditions were admitted such as
cerebrovascular disease or myocardial infarction within
the past year, uncontrolled hypertension while receiving
chronic medication, unstable angina, New York Heart
Association class II-IV congestive heart failure, serious
cardiac arrhythmia requiring medication, major trauma
within the past 28 days, serious non-healing wound,
ulcer or bone fracture, evidence of bleeding diathesis
or coagulopathy or inability to take oral medication.
Evidence of metabolic dysfunction, unknown dihydro-
pyrimidine dehydrogenase deficiency, major surgery in the
4 weeks prior to the start of study treatment, no concurrent
chronic, daily treatment with aspirin (>325 mg/day) and
more than 10 days since prior use of full-dose oral or
parenteral anticoagulants for therapeutic purposes were
also exclusion criteria. Local Ethical Committee ap-
proved the trial: Comité de Ética de Investigación Clín-
ica del Hospital Universitari de Bellvitge, Edifici Unitat
de Recerca, Feixa Llarga, s/n, 08907 L'Hospitalet de
Llobregat (Barcelona).
Treatment plan and dose modifications
Bevacizumab was supplied by Roche (Madrid, Spain) in
commercially available formulations. Patients received
capecitabine plus bevacizumab with concomitant radio-
therapy as follows: BVZ initially was administered at
10 mg/kg over a period of 90 minutes (±15 min). Doses
of BVZ were administered at 5 mg/kg on days 15th,
29th and 43rd. No modification of the dose of BVZ was
allowed throughout the study, unless the patient's weight
varied ≥ 10% over the same, compared to baseline body
weight. Capecitabine started after the 2nd infusion BVZ
(second cycle) at a dose of 900 mg/m2 administered orally
(po) every 12 hours (total daily dose of 1800 mg/m2). The
first dose of capecitabine was administered in the evening
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dosing schedule of twice daily for 5 days a week. Patients
received radiotherapy in the study consisting of a total
dose of 45 Gy in 1.8 Gy dose, per session, over 5 sessions/
week for 5 weeks (Energy: Megavoltage photons preferably
6–18 Mv). Surgical resection was scheduled 6–8 weeks
after therapy completion. The surgical strategy was at
the discretion of the surgeon based on the experience
of the working group. After recovery from surgery,
patients received adjuvant chemotherapy with regimen
selection at the discretion of the treating medical on-
cologist. Toxicities were evaluated according the National
Cancer Institute Common Toxicity Criteria 3.0.
Study assessments
All patients were initially evaluated with a collection of
history, physical examination, chest X-ray, complete
blood cell (CBC) count, liver and kidney function tests,
pregnancy test if female and ECG. Computed tomography
(CT) of the abdomen and pelvis was performed; Colonos-
copy with biopsy, endoscopic ultrasound and surgical
evaluation were performed in all cases. Carcinoembrio-
nync antigen (CEA) was measured at the baseline and
after completion of radiation therapy and after surgery.
Magnetic resonance imaging (MRI) of the pelvis was
performed on all patients previous to any treatment. On
week 3 after the end of treatment an evaluation visit was
performed. A radical resection of the rectal tumor along
with an appropriate vascular pedicle and accompanying
lymphatic drainage was made. For tumors in the mid
and lower rectum total mesorectal excision (TME) was
carried out. However, for tumors in the upper rectum
(at or above 10 cm from the anal margin) the mesorec-
tum was resected at 5 cm or more distal to the tumor.
Tumour staging, pathological examination of the tumour
type and complications of surgery were evaluated at the
post-surgery visit.
The pathological response criteria and were defined as
follows: pathologic complete response: the absence of
tumor cells in the surgical specimen including lymph
nodes (ypT0N0); partial response: the dominant pres-
ence of fibrosis and tumor regression greater than 50%;
stable disease: the presence of fibrosis with tumor re-
gression less than 50%; progression of disease: absence
of tumor response and/or distant metastasis clinically
undetected before surgery. Antiangiogenic profile, con-
sisting of plasma samples, was obtained at baseline and
weeks 1 and 5, measuring VEGF-A and VE-cadherin.
These markers were evaluated by non-invasive techniques
enzyme-linked immunosorbent assay (ELISA) and Real-
Time PCR. Tumor samples were assessed for MVD by
immunohistochemistry at baseline and after surgery.
A radical resection (R0) was defined as the removal of
all macroscopic tumor tissue, no evidence of distantmetastases, the absence of microscopic tumor tissue,
free resection margins and lymphadenectomy extended
beyond involved nodes at postoperative pathological
examination. A resection was evaluated as non-radical
when microscopic (R1 ≤ 1 mm) or macroscopic (R2) re-
sidual tumor was found. Tumor downstaging was deter-
mined by comparing the pathological stage with the
baseline clinical TNM stage.
Adjuvant chemotherapy was administered according to
our local protocol as follows: Patients with ypT4 or ypN+
should receive 4 months of adjuvant chemotherapy with
oxaliplatin plus fluoropyrimidines (CAPOX –Capecitabine
plus Oxaliplatin- for 6 cycles or FOLFOX4 –folinic acid,
Fluorouracile and Oxaliplatin- for 8 cycles) and patients
with ypT0-3 N0 should receive 6 cycles with capecitabine
alone (1250 mg/m2/12 h for 14 days every 21 days).
Study design
The study was an open-label, unicentric, un-controlled
phase II study conducted using a Simon optimal two-
stage phase II design [12]. The primary efficacy end-
point was pCR rate, defined as a complete regression of
the tumor with lack of tumoral cells, only fibrosis or
mucin after an exhaustive sampling of the tumoral zone.
With an α error of 0.05 and β error of 0.20, an initial
sample of 18 patients was treated following these rules:
If no pathological responses were seen in these first 18
patients, the combination would be rejected for further
study; if at least one response was seen, 25 additional
patients would enter the study in order to achieve a
given standard error of the estimated pCR rate.
Secondary end-points were: overall clinical response
rate: percentage of patients with complete and partial
clinical response; downstaging rate: percentage of pa-
tients with improved tumour staging compared to base-
line; local control rate: percentage of patients who get
resection R0.
Overall survival (OS), defined as the elapsed time from
baseline to date of the death of the patient due to any
cause. Disease Free Survival (DFS) determined as time
from surgery to recurrence (local or remote) of disease or
death from any cause (whichever comes first). Overall sur-
vival and DFS were calculated using Kaplan Meier Method.
Confidence intervals (CI) at 95% were estimated using nor-
mal approximation.
Summary tables (absolute and relative frequencies)
were used for the descriptive analysis of categorical vari-
ables. Statistical analyses were performed using SAS
version 9.2.
Numerical descriptive analyses were performed for
VEGF and VE-CAD plasma levels at baseline, week 1
and week 5. The U de Mann–Whitney test was applied
in order to detect time changes between baseline vs
week 1, baseline vs week 5 and week 1 vs week 5.
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at each surgery tumor sample, and the value considered
for the statistical analysis was the weighted average of all
of them. Numerical descriptive analysis was performed
for this variable. An univariated Cox regression model
was further used in order to evaluate the influence of
microvessel density in time efficacy variables.
Association with other prognostic factors was also
analysed through Cox proportional hazard model. Data
were reported as Hazard Rate Ratios and 95% CI through
likehood ratio test. Remark guidelines were followed [13].
Results
Between July 2007 and July 2010, 43 patients were en-
tered into the study, of whom 2 patients were excluded
from the intention to treat (ITT) population because of
withdrawal of informed consent (n = 1) and lost to
follow-up before the start of treatment protocol (n = 1).
One further patient was withdrawn from the analysis be-
cause of unconfirmed LARC (Figure 1).
Patient characteristics at baseline are shown in Table 1.
Thirty-eight patients completed neo-adjuvant treatment
and one patient withdrawn from treatment underwent
surgery, therefore in total, 39 patients were surgically
treated. Surgery details were as follows: radical surgery
was performed in 38 patients (97,4%) and one patient
was underwent palliative surgical treatment. Thirty pa-
tients were operated by anterior resection (76,9%) and 9
by abdominoperineal amputation (23,1%). Total mesor-
ectal excision was done for 25 patients (69,4%) the
remaining patients undergoing surgery had a partial
mesorectal excision (PME) due to their tumors wereFigure 1 Disposition of enrolled patients.located at the upper rectum, R0 resection was obtained
for 33 patients (84,6%) and 31 (79,5%) preserved sphinc-
ter function. Hospital length of tay was 14,4 days, mean ±
SD, 11.5. Thirteen patients suffered post-operative compli-
cations (13/39: 33.3%). Most frequent complications
were: wound infection (6: 40%), intraabdominal collec-
tion (3: 20%), suture dehiscence (2: 13.3%), ileus para-
lytic (2: 13.3%) and pelvic/presacral collection (2:
13.3%).
Regarding adjuvant treatment: 33 patients received
4 months of adjuvant chemotherapy, 17 patients with
capecitabine because they were ypT0-3 N0 and 16 pa-
tients received capecitabine or 5FU plus oxaliplatin be-
cause they were ypN+ or ypT4. One patient received
palliative chemotherapy. Three patients couldn’t receive
adjuvant chemotherapy because they had suffered some
surgery complications that affected their performance
status. Finally, 2 patients did not receive chemotherapy
because they presented a cardiac problem (one of them
at post operative period). Chemotherapy was started 4 to
8 weeks after surgery.Efficacy
Three patients had a pathological complete response
(3/40: 7.5%) and 27 (67.5%) had a pathological partial
response, for an overall pathological response rate of
75%. A further 8 patients (20%) had stable disease, giving
a disease control rate of 95%. One of the remaining
patients suffered disease progression and another one
did not undergo surgery. Of the partial response pa-
tients, 8 had a partial microscopical residual response
Table 2 Response of primary tumor and nodal status*
Response N (%)
ypT:
0 3 (7.5)
1 1 (2.5)
2 12 (30.0)
3 22 (55.0)
4 1 (2.5)
Not available* 1 (2.5)
ypN:
0 25 (62.5)
1 13 (32.5)
2 1 (2.5)
Not available* 1 (2.5)
Tumor regression grade:
1 3 (7.0)
2 8 (20.0)
3 19 (47.5)
4 9 (22.5)
Not available* 1 (2.5)
*One patient did not undergo surgery.
Table 1 Patient characteristics at baseline (n = 40)
Patient characteristics Value
Median (range) age, years 63 (54–66)
Gender, n (%)
Male 30 (75.0)
Female 10 (25.0)
ECOG PS, n (%)
0 20 (50.0
1 20 (50.0)
TNM status, n (%)
T3* 32 (80.0)
T3a 3 (7.5)
T3b 1 (2.5)
T3c 2 (5.0)
T4 2 (5.0)
Nx 1 (2.5)
N0 1 (2.5)
N1 24 (60.0)
N2 14 (35.0)
*It was not specified if the T3 status was T3a, T3b or T3c.
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One patient did not have this data (Table 2).
Downstaging occurred in 31 (31/40: 77.5%) of the
patients evaluated.
Safety
In total, 3 patients (7.3%) withdrew from the study. Rea-
sons for study discontinuation were: toxicity or other
adverse event or concomitant disease (2, 4.9%) and non-
compliance of selection criteria (1, 2.4%).
Leucopenia was present in 5 patients, two of them
grade 2 and three grade 3, and neutropenia appeared as
grade 1–3 in 7.3% of patients. Lymphopenia was the
most commonly observed event, occurring in 9.8% of
patients (all related to capecitabine and 4.9% to bevaci-
zumab). Non-hematological adverse events are summa-
rized in Table 3.
Two patients died during the follow-up period because
of pneumonia (n = 1) and pneumothorax (n = 1) that
were considered not related to study treatment. At the
time of this analysis, only 2 patients have relapsed locally
and another 4 patients have presented metastatic disease.
Only one patient has died due to underlying cancer.
Biomarkers profile
Plasma samples were available for 33 patients (details
are shown in Table 4). No statistically significant differ-
ences were found between baseline levels and levels
achieved at week one and 5 (Baseline vs week 1: VEGF
57 pg/ml (p-value 0.1763) and VE-cadherin 22 ng/ml(p-value 0.3652); Baseline vs week 5: VEGF 16 pg/ml (p-
value 0.4961) and VE-cadherin 13 ng/ml (p-value
0,5469); week 1 vs week 5: VEGF 23 pg/ml (p-value
0.6953) and VE-cadherin 10 ng/ml (p-value 0.0839) and
no correlations were observed between values and efficacy
variables. Tumor samples were available for 37 patients.
Median MVD was 14 (8,2-33,6) and no correlation was
seen with standard prognostic variables as CEA, nodal
status, local control, DFS and OS.
Outcome
The median follow up of the study population is
40 months, range 13 to 57, local control rate at 4 years
is 89.7% (95% CI 67–97), median not reached and DFS rate
at 4 years is 68.7% (95% CI 51–81) median not reached
with an OS rate of 91.8% at 4 years (95% CI 80–96.7),
median not reached.
Discussion
This is a study with BVZ combined with chemoradio-
therapy in patients with LARC that was designed to
achieve a 25% of pCR rate. Although the main endpoint
was not reached, higher than expected rates of partial
microscopical residual response, R0 resection, sphincter-
preservation and tumor downstaging were observed, and
moreover, data of DFS and OS are encouraging.
Several phase I and II trials have tested the combin-
ation of BVZ administered concomitantly with chemo-
radiotherapy in patients with LARC in different schedules,
Table 3 Nonhematologic Toxicity
Grade (no. of patients)
Toxicity 1 2 3 4
Asthenia 37 2 0 0
Dhiarrea 26 5 1 0
Hypertension 4 1 0 0
Anorexia 9 0 0 0
Disuria 7 0 0 0
Mucositis 8 0 0 0
Abdominal pain 1 6 0 0
Hand-foot syndrome 11 0 0 0
Vasospastic angina 0 0 0 1
Nauseas 4 0 0 0
Radiodermitis 3 1 1 0
Disphonia 3 0 0 0
Rectitis 2 1 0 0
Stomatitis 2 0 0 0
Vomiting 2 0 0 0
Rectorraghia 1 2 0 0
Anal pruritus 3 0 0 0
Other* 1 0 0 0
Worst grade per patient (n = 41).
*Arthralgia, disphonia, eritema, gastric pain, abdominal discomfort, rash, fever,
vomiting, tenesmus (1 each one, grade 1–2).
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their biological behavior. All of these studies had the ex-
pectation of improving the pathological complete response
rate to therapy as a surrogate marker of the improvement
in disease and overall survival [10,14-24].
Table 5 shows a summary of studies containing bevaci-
zumab which have been published so far. The first point
which can be drawn from these studies is that most of
them have demonstrated the feasibility of the adminis-
tration of the combination of these four therapeutic
strategies (chemotherapy, radiotherapy, and surgery and
antiangiogenic therapy). With the exception of studies of
Dipetrillo et al. and Resch et al. [22] all conclude that this
combination of treatments can be administered in a realis-
tic and affordable approach to the population of patientsTable 4 Descriptive values of angiogenic biomarkers
N NA Min Q1
VEGF (pg/ml) Baseline 33 12 16,4 57,8
Week 1 33 15 3,3 12,0
Week 5 33 21 45,6 58,2
VE-cadherin (ng/ml) Baseline 33 9 1,5 3,4
Week 1 33 17 2,5 3,5
Week 5 33 22 3,1 3,8
N: number; NA: not available; Min: minimum; Q1; quartile 1; Q3: quartile 3; Max: mawith this disease. Similarly, the trial of our group shows a
treatment schedule feasible and tolerable. The adverse
event profile observed during this study was comparable
to those reported in other studies involving capecitabine
plus bevacizumab with concurrent radiotherapy.
Particularly striking is the disparity between the tox-
icity observed by Dipetrillo et al. and Resch et al. [22]
compared to other studies, which a priori does not seem
attributable to differences in the doses of the individual
components of the treatment regimens. Furthermore,
there is some variability with respect to the sample of
patients included in each of them, which could produce
an effect on results due to selection bias, which consist-
ently operates in the literature against the outcomes
observed in phase 2 studies. Similarly, the results in
terms of pathologic complete response rates vary from
7.5% in our case, to 36% in the case of Nogué et al. [18],
although such discrepancies have been observed previ-
ously with other phase 2 trials in these patients. Placed in
the context of previous larger phase III studies with
chemo-radiotherapy (13.9% to 19.2% pCR rates in Gerard
et al. study and 16% in the study of Aschele et al.) [7,8]
and pooled analyses (pCR rate of 15.6%) [6] despite the in-
consistency in the results, which may be due to interob-
server variability or the increasing rate of pCR rate
reported after a longer interval between the chemoradio-
therapy and surgery without reduction in local relapse and
overall survival [25] these rates remain promising.
A long follow-up is needed to assess the impact on
other and more important efficacy endpoints, as DFS
and OS. In our study, despite the narrow pathological
complete response rate, the prolonged median follow-up
shows the good results that so far have been observed in
survival. If the use of bevacizumab in the treatment of
primary rectal tumors improves survival outcomes of
patients and disease-free survival, it is something that
for now remains hypothetical. Data reported by Willet
et al. [26] and the results derived from our study suggest
that the antiangiogenic therapy with bevacizumab can
prevent the emergence and establishment of metastases
in these tumors because of the promising survival rates
(69% DFS and 95% OS at 5 years), although further ran-
domized studies are warranted.Median Mean Q3 Max Stdev Var
90,5 91,3 114,7 211,2 54,0 2915,9
40,5 47,7 69,3 139,8 41,0 1680,6
79,4 81,4 95,7 158,8 31,8 1014,4
4,3 4,4 5,3 9,4 1,8 3,1
3,9 4,5 5,4 7,3 1,4 2,1
5,0 5,0 5,7 7,3 1,4 1,9
ximum; STdev: standard deviation; Var: variance.
Table 5 summary of studies with chemoradiotherapy plus bevacizumab
Study Phase N. of patients Staging Radiotherapy Gy/
fractions/weeks
Bevacizumab Concomitant chemotherapy pCR N.% Downstaging N.% R0%
Czito et al. [14] I 11 II-IV 50.4/28/5.5 15 mg/Kg 1st dose Capecitabine: 500–825 mg/m2/bid
5 days/week
2/11 18.2% Overall: 81.8% 81.8%
10 mg/Kg days 8, 22 Oxaliplatin 50–75 mg/m2/1, 8,
15, 22, 29
Willett et a [10] II 32 T3-T4 50.4/28/5.5 5-10 mg/Kg days 1, 8, 15, 22 Fluorouracile: 225 mg/m2/24 hours/
4 cycles
5/32 16% T stage: 50% N stage:
56.5%
93.7%
Crane et al. [16] II 25 T3N0/T3N1 50.4/28/5.5 5 mg/Kg 3 doses Capecitabine: 900 mg/m2/bid
5 days/week
8/25 32% T stage: 64% N
stage: 15%
100%
Nogué et al. [18] II 47 T3N0-T4N2 50.4/25/5.5 7 mg/Kg induction 4 cycles Capecitabine: 825 mg/m2/bid
5 days/week
16/45 36% - 97.9%
5 mg/Kg days 1, 15, 29
Koukourakis et al. [17] II 19 T3 and/or N+ Hypofractionated
accelerated
5 mg/Kg 2 doses Capecitabine: 600 mg/m2/bid
5 days/week
7/19 36.8% - -
[19] II 61 T2N1-T4N2 50.4/28/5.5 5 mg/Kg days −14, 1, 15, 29 Capecitabine: 825 mg/m2/bid
5 days/week
8/60 13.3% T stage: 64% N stage:
15% Overall: 73.8%
95%
Dipetrillo et al. [20] II 26 T2N0-T4Nx 50.4/25/5.5 5 mg/Kg days induction and
then days 1, 15, 29
Fluorouracile: 200 mg/m2/24 hours 5/25 20% - -
Oxaliplatin 50 mg/m2/1, 8, 15,
22, 29, 36
Landry et al. [24] II 57 T3-T4 50.4/28/5.5 5 mg/Kg days 1, 15, 29 Capecitabine: 825 mg/m2/bid
5 days/week
9/57 17% Overall: 59% -
Oxaliplatin 50 mg/m2/1, 8, 15,
22, 29
Gasparini et al. [21] II 43 T2N1-T4N2 50.4/28/5.5 5 mg/Kg days −14, 1, 15, 29 Capecitabine: 825 mg/m2/bid
5 days/week
6/43 14% T Stage: 34.9% N
stage: 41.86%
-
Spigel et al. [23] II 35 (cohort A) II/III 50.4/28/5.5 5 mg/Kg days 1, 15 Fluorouracile: 225 mg/m2/
24 hours
days 1 to 42
10/35 29% - -
Resch et al. [22] II 8 cT3 45/-/5 5 mg/Kg days 1, 15, 29 Capecitabine: 825 mg/m2/bid
5 days/week 4 weeks
2/8 25% Overall: 37.5% -
Kennecke et al. [15] II 42 T2-T4 N2 50.4/28/5.5 5 mg/Kg days −14, 1, 15, 29 Capecitabine: 825 mg/m2/bid
days 1–14, 22-35
7/42 18.4% - 92%
Oxaliplatin 50 mg/m2/1, 8, 22, 29
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trial of this regimen, performed by the Spanish TTD Col-
laborative Group (AVAXEL trial) whose results are awaited.
Conclusion
The administration of bevacizumab in addition to a
standard neoadjuvant capecitabine-based chemoradio-
therapy regimen in patients with LARC is feasible and
its efficacy is sufficient to justify further randomized
studies. Biological data concurrent to standard treatment
can add information to elucidate the role of antiangio-
genic treatment. Current long-term follow-up results are
promising and can help to determine the benefits of
adding bevacizumab to the regimen.
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